Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.37 |
| ▸ | UGCG | Q16739 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468097 | 0.92 | LRRK2 (0.37) | GPR119UGCGHCRTR2IRAK4EGLN2 | |
| SCHEMBL30468081 | 0.90 | EGLN2 (0.35) | GPR119UGCGIRAK4EGLN2SSTR4 | |
| SCHEMBL30468013 | 0.90 | GPR119 (0.37) | GPR119IRAK4 | |
| SCHEMBL30467989 | 0.89 | USP30 (0.37) | GPR119HCRTR2HCRTR1SSTR4SSTR1 | |
| SCHEMBL26388409 | 0.88 | UGCG (0.36) | UGCGSSTR4SSTR1ABL1 | |
| SCHEMBL30467984 | 0.88 | UGCG (0.36) | UGCGSSTR4SSTR1ABL1 | |
| SCHEMBL22585734 | 0.83 | FAAH (0.43) | GPR119HCRTR2EGLN2 | |
| SCHEMBL30467997 | 0.82 | EGLN2 (0.37) | GPR119UGCGIRAK4EGLN2AR | |
| SCHEMBL30468015 | 0.81 | IRAK4 (0.36) | GPR119IRAK4EGLN2 | |
| SCHEMBL23085845 | 0.80 | LRRK2 (0.37) | GPR119UGCGHCRTR2IRAK4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4161920-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP1, USP47 | GPR119 4205/4885UGCG 3329/4885HCRTR2 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.